In this presentation, Anand A. Patel, MD, reviewed the contemporary standard-of-care treatment roadmap for AML in 2025, covering key phases like induction chemotherapy (eg, the “7+3” regimen), consolidation…
Eunice S. Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, New York, discusses the treatment strategies for patients who develop secondary acute myeloid leukemia (AML) following hypomethylating agent…
Heat Biologics has devised a method intended to capture poly-antigens and present them to immunomodulatory mechanisms and revitalize the immune system, allowing it to target and annihilate cancer.
Current therapeutic options for non-small cell lung cancer (NSCLC) are ever-evolving with the possibility of solely immunotherapy-based treatment regimens on the near horizon for certain patients.
Optimizing an extracellular matrix scaffold for ovarian follicle implantation helps create successful bioprosthesis for restoring fertility in sterile mice.
